Obesity in United Kingdom 2026
Obesity has moved from a background health concern to one of the defining public health stories of the decade in Britain. The latest Health Survey for England data, published in January 2026, confirms that 30% of adults are now living with obesity, and this figure sits alongside a widening gap between the four nations, a rising child obesity trend, and a fast-changing NHS drug access landscape that has put semaglutide and tirzepatide at the centre of national conversation. Whether the driver is diet, inactivity, deprivation, or genetics, the scale of the numbers means obesity now touches nearly every NHS department, from cardiology to orthopaedics to mental health services.
What makes 2026 different from previous years isn’t just the prevalence figures — it’s the arrival of GLP-1 weight-loss medicines into mainstream primary care. Tirzepatide (Mounjaro) is now being prescribed through GP surgeries under a phased NHS rollout, while semaglutide (Wegovy) remains gated behind specialist weight management services. This article pulls together the most current, verified UK obesity statistics for 2026 — prevalence by nation and region, child measurement data, economic cost estimates, and exactly how GLP-1 access works today — so you have a single, accurate reference point for where Britain’s obesity crisis actually stands, drawn only from official NHS, government, and peer-reviewed sources rather than marketing claims from weight-loss brands.
Obesity Facts UK 2026
| Fact | Figure |
|---|---|
| Adults living with obesity in England (2024 data) | 30% |
| Adults overweight or obese in England | 66% |
| Estimated UK adults living with obesity | 14.15–18.11 million |
| Adults taking weight-loss drugs in the UK | 2.4 million |
| NHS hospital admissions with obesity as a factor (2022/23) | 1.2 million+ |
| Total annual cost of obesity to the UK economy | £126 billion |
| Reception-age children (4–5) obese, 2024/25 | 10.5% |
| Year 6 children (10–11) obese, 2024/25 | 22.2% |
| Region with highest obesity rate | North East, 39% |
| Projected UK adults obese by 2040 | 21 million (36%) |
Source: NHS England Digital, Office for Health Improvement & Disparities, National Child Measurement Programme, Nesta/Frontier Economics
These headline figures tell a story that’s easy to summarise but hard to reverse: roughly one in three UK adults is now classed as obese, and two in three carry excess weight of some degree. What’s notable in the 2026 data is that this isn’t a plateau — the Health Survey for England’s 30% figure is the highest measured adult obesity rate ever recorded in the country, and it continues a trend that has been climbing steadily since the 1990s, when the equivalent figure sat closer to 13%. The 2.4 million people already using GLP-1 medicines, most of them paying privately rather than through the NHS, shows just how large the gap is between demand for treatment and what the health service can currently fund.
The economic figures are arguably the most striking part of the table. A £126 billion annual cost to the UK economy is a number large enough to reframe obesity as a fiscal issue as much as a clinical one, and the 1.2 million obesity-linked hospital admissions in a single year illustrate the downstream pressure on NHS capacity — everything from joint replacements to diabetes complications to cardiac care. Meanwhile, the child measurement data matters because it’s predictive: obesity prevalence roughly doubles between Reception and Year 6, meaning the 10.5% and 22.2% figures aren’t just a snapshot of childhood health but an early signal of where the adult obesity rate is heading over the next decade.
Adult Obesity Rate Statistics in UK 2026
| Nation | Adult Obesity Rate (Latest Measured/Reported) |
|---|---|
| Scotland | 31% |
| England | 30% |
| Northern Ireland | ~28% |
| Wales (self-reported) | 25–26% |
| Wales (Nesta-adjusted estimate) | ~34% |
Source: Health Survey for England 2024, Scottish Health Survey 2024, Health Survey Northern Ireland 2023/24, National Survey for Wales
England’s 30% adult obesity figure comes from measured height and weight data collected as part of the Health Survey for England, which is generally treated as the most reliable of the four national surveys because it doesn’t rely on people accurately reporting their own weight. Scotland actually edges ahead at 31%, the highest of the four nations, based on the most recent Scottish Health Survey. Northern Ireland sits close behind at roughly 28%, while Wales reports the lowest official figure at 25–26% — though that number comes from self-reported data via the National Survey for Wales, and adjusted analysis from Nesta suggests the true figure once under-reporting is corrected could be closer to 34%, which would actually make Wales the worst-affected nation rather than the best.
This measured-versus-self-reported distinction is one of the most important things to understand when comparing UK obesity statistics across regions or years. Men are consistently more likely to be overweight or living with obesity than women — the Health Survey for England found 70% of men classed as overweight or obese compared with 62% of women — and this gender gap holds fairly steady across all four nations. What the four-nations comparison ultimately shows is that obesity in the UK isn’t a single national problem with one driver; it’s four overlapping trends shaped by different survey methods, different regional economies, and different levels of deprivation, which is exactly why a single UK-wide percentage can be misleading without this level of breakdown.
Regional Obesity Statistics UK 2026
| Region | Adult Obesity Rate |
|---|---|
| North East England | 39% |
| National (England) average | 30% |
| Most deprived areas (general pattern) | Significantly above average |
| Least deprived areas (general pattern) | Significantly below average |
Source: Office for Health Improvement & Disparities, Obesity, Physical Activity and Nutrition Profile, May 2026 update
The regional obesity picture inside England is arguably more revealing than the national figure alone. The North East recorded an obesity rate of 39%, meaning close to four in ten adults in the region are classed as obese — nearly ten percentage points above the national average of 30%. This isn’t an isolated statistic; it reflects a long-documented pattern in the government’s Obesity, Physical Activity and Nutrition Profile data, where northern and post-industrial regions consistently report higher obesity prevalence than London and the South East, correlating closely with income, employment type, and access to fresh food.
Deprivation is the thread running through almost every regional and demographic breakdown in the 2026 data. Areas with higher levels of socioeconomic deprivation report obesity rates that are consistently and substantially higher than in wealthier areas, a pattern that holds true in both adult and child data. For context on how weight-related conditions translate into serious illness, the Heart Disease Statistics in UK report shows a similar regional and deprivation-linked pattern, which isn’t a coincidence given how closely cardiovascular risk tracks with excess weight. The scale of the North East’s gap also helps explain why NHS weight management funding and GLP-1 rollout priorities have leaned toward high-need areas first, rather than a uniform national approach.
Child Obesity Statistics UK 2026
| Age Group | Obesity Rate (2024/25) | Most Deprived Areas | Least Deprived Areas |
|---|---|---|---|
| Reception (4–5 years) | 10.5% | 14.0% | 6.9% |
| Year 6 (10–11 years) | 22.2% | 29.3% | 13.5% |
Source: National Child Measurement Programme, NHS England Digital, November 2025 annual report
The National Child Measurement Programme, which measures the height and weight of children in Reception and Year 6 across mainstream state schools in England, found that 10.5% of Reception-age children were obese in the 2024/25 school year — one of the highest rates recorded since the programme began in 2006/07. By Year 6, that figure more than doubles to 22.2%, showing that the gap between healthy weight and obesity widens considerably during primary school years rather than narrowing.
The deprivation split within these figures is the part public health officials watch most closely, because it shows the gap is getting wider rather than closing. In Reception, children in the most deprived areas are obese at more than double the rate of children in the least deprived areas (14.0% versus 6.9%), and by Year 6 that gap has widened further to 29.3% versus 13.5%. This means a child’s postcode has become one of the strongest predictors of childhood obesity in England, and because early obesity strongly predicts adult obesity, this deprivation gap is effectively being carried forward into the next generation’s adult health statistics.
GLP-1 Weight Loss Drug Access UK 2026
| Medicine | NHS Access Route | Key Eligibility (Phase 1) |
|---|---|---|
| Mounjaro (tirzepatide) | GP practices (from April 2026) + specialist services | BMI 40+ with 4 or more weight-related conditions |
| Wegovy (semaglutide) | Tier 3 specialist weight management services; new cardiovascular route from April 2026 | BMI 35+ (32.5+ for some ethnic groups) with 1+ condition |
| Saxenda (liraglutide) | Specialist services only; limited ICB commissioning | Varies by area |
Source: NHS England, NICE Technology Appraisal TA1026, NHS Cheshire and Merseyside
The biggest structural shift in UK obesity treatment for 2026 is that tirzepatide (Mounjaro) can now be prescribed directly by GPs, following NICE’s December 2024 recommendation and its incorporation into the 2026/27 GP contract through a new Quality and Outcomes Framework indicator. Previously, every GLP-1 medicine for weight management in the UK required a referral into a Tier 3 specialist service — a bottleneck that left most people waiting months or turning to private prescriptions instead. Mounjaro’s Phase 1 criteria are still tightly drawn, requiring a BMI of 40 or above plus four or more weight-related conditions from a defined list that includes type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, and obstructive sleep apnoea, with GP participation in the scheme currently voluntary rather than universal.
Wegovy, by contrast, remains locked into the older specialist-referral pathway for standard weight management, though April 2026 brought a second route: NICE approval for semaglutide to reduce cardiovascular risk in people with established heart disease, which can now be accessed via a GP or cardiologist rather than a weight clinic. NHS England’s own target for the rollout is up to 220,000 patients treated in the first three years, against an estimated 3.4 million people who could eventually qualify over a 12-year phased programme — a gap that explains why roughly 2.4 million people are already sourcing GLP-1 medicines privately, at a typical UK cost of £150–£250 per month. Readers wanting the fuller picture of how these medicines are being used, and their reported side-effect profile, can find more detail in the GLP-1 Ozempic Statistics report, which covers usage trends beyond the NHS pathway specifically.
Economic Cost of Obesity UK 2026
| Cost Category | Annual Figure |
|---|---|
| Total cost to UK economy | £126 billion |
| Years of good-quality life lost (QALYs) | £71.4 billion |
| Lost productivity (absenteeism, presenteeism, inactivity) | £30.8 billion |
| Direct NHS treatment cost | £12.6 billion |
| Informal care costs | £10.5 billion |
| Formal social care costs | £1.2 billion |
Source: Nesta and Frontier Economics, 2025 economic analysis
The most detailed cost breakdown available for 2026 comes from the Nesta and Frontier Economics analysis, which puts the total economic burden of obesity and excess weight in the UK at £126 billion a year. The largest single component isn’t NHS spending at all — it’s the £71.4 billion valuation placed on years of good-quality life lost to weight-related illness, a figure that captures the human cost of conditions like type 2 diabetes, joint disease, and certain cancers rather than just their treatment bills. Lost productivity, at £30.8 billion, is often described by economists as roughly equivalent to a 3p cut in the basic rate of income tax, which gives some sense of scale for a non-specialist audience.
Direct NHS treatment costs of £12.6 billion are, perhaps surprisingly, the smaller line item in the overall breakdown, even though they’re the figure most commonly quoted in media coverage. Add informal care costs of £10.5 billion, largely absorbed by unpaid family carers, and formal social care spending of £1.2 billion, and the picture that emerges is one where obesity’s financial burden is spread far more widely across the economy than NHS budgets alone. Separately, NHS England logged more than 1.2 million hospital admissions in 2022/23 where obesity was recorded as a contributing factor — equivalent to over 3,000 admissions a day, a figure that has roughly doubled since 2016/17 and puts direct pressure on NHS workforce capacity; the NHS Workforce Statistics breakdown shows how stretched staffing levels intersect with exactly this kind of rising admission volume.
Obesity Projections and Future Trends UK 2026
| Projection | Estimate (by 2040) |
|---|---|
| UK adults classed as obese | 21 million (36%) |
| UK adults overweight or obese combined | 71% |
| Trend since the 1990s | Adult obesity roughly doubled |
| Recorded obesity in NHS records, 2019 vs 2025 | 26.3% → 30.3% |
Source: Cancer Research UK overweight and obesity prevalence projections; nationwide NHS records analysis, 54 million adults, published June 2026
Longer-term projections from Cancer Research UK paint a fairly stark trajectory: if current patterns continue unchanged, around 21 million UK adults — roughly 36% of the population — could be classed as obese by 2040, with 71% either overweight or obese. That would represent a further significant increase from today’s already-record levels, and it builds on a trend that has already seen adult obesity roughly double since the 1990s, when the rate sat closer to 13%.
A separate, more immediate data point reinforces that this rise isn’t just a future projection — it’s already happening in real time. A nationwide analysis of NHS electronic health records covering more than 54 million adults found that recorded obesity prevalence in England climbed from 26.3% in 2019 to 30.3% by April 2025, with the researchers noting that the burden is rising fastest in the most disadvantaged communities. What both data sets point to is a widening gap rather than a converging one: between nations, between regions, between deprivation levels, and between the small proportion of patients currently able to access NHS-funded GLP-1 treatment and the millions who remain outside the eligibility criteria for now.
What’s worth stressing about these 2040 projections is that they assume no major change in policy, treatment access, or public behaviour — they’re a continuation of the current trajectory rather than a fixed outcome. The gap between the 26.3% recorded rate in 2019 and the 30.3% figure in 2025 shows the pace of change over just six years, and if that rate of increase were to continue unchecked through to 2040, the 36% projection from Cancer Research UK starts to look conservative rather than alarmist. This is part of why NHS England’s GLP-1 rollout, community pharmacy pilots, and QOF prescribing incentives for GPs are being treated as urgent policy tools rather than routine service updates — the current trajectory suggests that treatment access will need to expand considerably faster than its present phased schedule if it’s going to meaningfully bend the national curve before 2040 rather than simply keep pace with a shrinking share of the growing patient population.
Obesity-Related Health Conditions UK 2026
| Condition Linked to Obesity | Relevance to UK Obesity Data |
|---|---|
| Type 2 diabetes | Qualifying condition for Mounjaro NHS access |
| Cardiovascular disease | Qualifying condition; also new Wegovy access route |
| Obstructive sleep apnoea | Qualifying condition for Mounjaro NHS access |
| Osteoarthritis and joint disease | Major driver of hospital admissions |
| Certain cancers | Included in long-term obesity risk data |
| Depression and related mental health impact | Recognised comorbidity in NHS guidance |
Source: NHS England Medicines for Obesity guidance; NICE Technology Appraisal TA1026
Obesity in the UK rarely shows up as an isolated diagnosis — it’s almost always discussed alongside a cluster of related conditions, and this is reflected directly in how NHS eligibility criteria for GLP-1 medicines are written. Type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, hypertension, and dyslipidaemia all appear on the qualifying list for Mounjaro’s primary care rollout, which effectively means the NHS has built its weight-loss drug access criteria around the very comorbidities that obesity statistics consistently show driving hospital admissions and long-term healthcare costs. This overlap is precisely why the 1.2 million obesity-linked hospital admissions figure spans so many different departments rather than concentrating in one area of care.
Joint disease and osteoarthritis are a particularly significant driver of NHS demand connected to excess weight, given the mechanical load extra body mass places on hips and knees over time, while the mental health dimension — depression and reduced quality of life associated with obesity — is increasingly recognised in NHS guidance as a comorbidity worth addressing alongside physical health outcomes rather than treating as a separate issue. Taken together, these overlapping condition categories help explain why obesity statistics for the UK in 2026 are rarely discussed in isolation; from a data and policy standpoint, obesity functions less like a single condition and more like a common upstream risk factor sitting behind a wide range of the country’s biggest chronic disease burdens.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
